Notice of a Meeting of a Working Group of the NIH Advisory Committee to the Director, 51827 [2010-20860]
Download as PDF
Federal Register / Vol. 75, No. 162 / Monday, August 23, 2010 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
erowe on DSK5CLS3C1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Recombinant DNA
Advisory Committee.
Date: September 15–17, 2010.
Time: September 15, 2010, 1:30 p.m. to
5:30 p.m.
Agenda: The Office of Biotechnology
Activities (OBA) and NIH Recombinant DNA
Advisory Committee will review and discuss
selected human gene transfer protocols as
well as related data management activities.
Please check the meeting agenda at https://
oba.od.nih.gov/rdna_rac/rac_meetings.html
for more information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Executive Meeting Center,
Rockville, MD 20852.
Time: September 16, 2010, 8 a.m. to 5:30
p.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols, have a
discussion of ethical considerations in
review of pediatric protocols, and discuss
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna_rac/rac_meetings.html
for more information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Executive Meeting Center,
Rockville, MD 20852.
Time: September 17, 2010, 8 a.m. to 1 p.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols, have a
discussion of ethical considerations in
review of pediatric protocols, and discuss
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna_rac/rac_meetings.html
for more information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Executive Meeting Center,
Rockville, MD 20852.
Contact Person: Chezelle George, Office of
Biotechnology Activities, Office of Science
Policy/OD, National Institutes of Health,
6705 Rockledge Drive, Room 750, Bethesda,
MD 20892. 301–496–9838.
georgec@od.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
oba.od.nih.gov/rdna/rdna.html, where an
agenda and any additional information for
the meeting will be posted when available.
VerDate Mar<15>2010
15:31 Aug 20, 2010
Jkt 220001
OMB’s ‘‘Mandatory Information
Requirements for Federal Assistance Program
Announcements’’ (45 FR 39592, June 11,
1980) requires a statement concerning the
official government programs contained in
the Catalog of Federal Domestic Assistance.
Normally NIH lists in its announcements the
number and title of affected individual
programs for the guidance of the public.
Because the guidance in this notice covers
virtually every NIH and Federal research
program in which DNA recombinant
molecule techniques could be used, it has
been determined not to be cost effective or
in the public interest to attempt to list these
programs. Such a list would likely require
several additional pages. In addition, NIH
could not be certain that every Federal
program would be included as many Federal
agencies, as well as private organizations,
both national and international, have elected
to follow the NIH Guidelines. In lieu of the
individual program listing, NIH invites
readers to direct questions to the information
address above about whether individual
programs listed in the Catalog of Federal
Domestic Assistance are affected.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: August 17, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
51827
the ongoing supplementary risk
assessment study being conducted for
the Boston University NEIDL.
The meeting will be open to the
public, with attendance limited to space
available. There will be a live webcast
of the meeting which can be accessed at
https://nihblueribbonpanel-bumc-neidl.
od.nih.gov/. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
Oral public comment will begin at
approximately 3 p.m. Written comments
may be provided, as well, by sending
them to the address below. Written
comments must be postmarked by
October 1, 2010 and should include the
name, address, telephone number and,
when applicable, the business or
professional affiliation of the
commenter.
A draft agenda and slides for the
meeting may be obtained by connecting
to https://nihblueribbonpanel-bumcneidl.od.nih.gov/. For additional
information concerning this meeting,
contact Ms. Kelly Fennington, Senior
Health Policy Analyst, Office of
Biotechnology Activities, Office of
Science Policy, Office of the Director,
National Institutes of Health, 6705
Rockledge Drive, Room 750, Bethesda,
MD 20892–7985; telephone 301–496–
9838; e-mail fennington@nih.gov.
[FR Doc. 2010–20861 Filed 8–20–10; 8:45 am]
Dated: August 16, 2010.
Amy P. Patterson,
Acting Director, Office of Science Policy,
National Institutes of Health.
BILLING CODE 4140–01–P
[FR Doc. 2010–20860 Filed 8–20–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Notice of a Meeting of a Working
Group of the NIH Advisory Committee
to the Director
The purpose of this notice is to inform
the public about a meeting of the NIH
Blue Ribbon Panel to Advise on the Risk
Assessment of the National Emerging
Infectious Diseases Laboratories (NEIDL)
at Boston University Medical Campus.
The meeting will be held Wednesday,
September 22, 2010 at the Hyatt
Regency Bethesda, 7400 Wisconsin
Avenue, Bethesda, MD 20814 from
approximately 8:30 a.m. to 3:30 p.m.
This meeting is the third in a series
of public meetings between the Blue
Ribbon Panel and the National Research
Council Committee on Technical Input
(NRC Committee) to review and discuss
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
E:\FR\FM\23AUN1.SGM
23AUN1
Agencies
[Federal Register Volume 75, Number 162 (Monday, August 23, 2010)]
[Notices]
[Page 51827]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-20860]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of a Meeting of a Working Group of the NIH Advisory
Committee to the Director
The purpose of this notice is to inform the public about a meeting
of the NIH Blue Ribbon Panel to Advise on the Risk Assessment of the
National Emerging Infectious Diseases Laboratories (NEIDL) at Boston
University Medical Campus.
The meeting will be held Wednesday, September 22, 2010 at the Hyatt
Regency Bethesda, 7400 Wisconsin Avenue, Bethesda, MD 20814 from
approximately 8:30 a.m. to 3:30 p.m.
This meeting is the third in a series of public meetings between
the Blue Ribbon Panel and the National Research Council Committee on
Technical Input (NRC Committee) to review and discuss the ongoing
supplementary risk assessment study being conducted for the Boston
University NEIDL.
The meeting will be open to the public, with attendance limited to
space available. There will be a live webcast of the meeting which can
be accessed at https://nihblueribbonpanel-bumc-neidl.od.nih.gov/.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the contact person listed below in advance of the meeting.
Oral public comment will begin at approximately 3 p.m. Written
comments may be provided, as well, by sending them to the address
below. Written comments must be postmarked by October 1, 2010 and
should include the name, address, telephone number and, when
applicable, the business or professional affiliation of the commenter.
A draft agenda and slides for the meeting may be obtained by
connecting to https://nihblueribbonpanel-bumc-neidl.od.nih.gov/. For
additional information concerning this meeting, contact Ms. Kelly
Fennington, Senior Health Policy Analyst, Office of Biotechnology
Activities, Office of Science Policy, Office of the Director, National
Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD
20892-7985; telephone 301-496-9838; e-mail fennington@nih.gov.
Dated: August 16, 2010.
Amy P. Patterson,
Acting Director, Office of Science Policy, National Institutes of
Health.
[FR Doc. 2010-20860 Filed 8-20-10; 8:45 am]
BILLING CODE 4140-01-P